The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 27 | — | 20.1x | Below average | |
Growth | 41 | 13.1% | 5.6% | Near average | |
Quality | 23 | -1404.1% | 7.6% | Below average | |
Safety | 22 | 0.9x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
VistaGen Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy VistaGen Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
VistaGen stock shows complete stability in the target price at 0.95 dollars over the past 7 and 30-day periods, with an absence of any recent revisions by analysts. This consistency reflects a state of waiting in the market, as current coverage is limited to only one analyst, leading to a lack of Dispersion in estimates but simultaneously raising the risks of relying on a unilateral opinion.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.